On Thursday, Shares of CVS Health Corp (NYSE:CVS), lost -1.43% to $99.22.
Stand Up To Cancer (SU2C), a program of the Entertainment Industry Foundation (EIF), and CVS/pharmacy, the retail division of CVS Health (CVS) declared recently a new print, radio and digital public service declaration (PSA) featuring award-winning actress and SU2C Ambassador Julie Bowen. The PSA aims to bring awareness to the importance of partnership in the fight against cancer and to encourage the general public to learn more and get involved. The PSA will start airing this month.
Like everyone in America, I have friends and family who have been affected by cancer. I know the importance of having the best team possible, working together – whether its people behind the scenes or those who work directly with the patient as they face a cancer diagnosis, said Stand Up To Cancer ambassador Julie Bowen. Through this PSA, we hope to assist people realize we all have a part in the battle against cancer. Im proud to be part of this campaign with Stand Up To Cancer and CVS Health, to assist illustrate that it takes a team to accelerate research and to improve cancer survival.
With this PSA, CVS Health reinforces its commitment to assisting people on their path to better health through the companys support of innovative cancer research. CVS Health has committed $10 million to SU2C over three years, supported by an annual in-store campaign. This will be the second year of the in-store fundraising campaign which will be held at CVS/pharmacy locations across the country from November 1 through November 28.
CVS Health Corporation, together with its auxiliaries, is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail Pharmacy and Corporate. The Pharmacy Services segment provides a range of pharmacy benefit administration (PBM) services and operates under the CVS/caremark Pharmacy Services, Novologix and Navarro Health Services names.
Shares of Amgen, Inc. (NASDAQ:AMGN), declined -1.52% to $143.51, during its last trading session.
Amgen declared the presentation of several studies evaluating Kyprolis® (carfilzomib) for Injection, a next-generation proteasome inhibitor, at the 15th International Myeloma Workshop (IMW), from Sept. 23-26, 2015, in Rome. Kyprolis is approved in the United States (U.S.) for use in combination with lenalidomide and dexamethasone for the treatment of relapsed multiple myeloma, an incurable blood cancer. In the European Union (EU), Kyprolis is under accelerated assessment with the European Medicines Agency (EMA).
Multiple myeloma has historically been one of the most difficult to treat diseases because of the inherent complexities related to the recurring pattern of remission and relapse, said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. Data to be presented at IMW will assist provide further insight into the potential of Kyprolis as an important treatment option…
Read More: Active Stocks News Recap: CVS Health (NYSE:CVS), Amgen, (NASDAQ:AMGN), Energy